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Abstract
Natural self-reactive antibodies in the peripheral blood may play a considerable role in the control of potentially toxic
proteins that may otherwise accumulate in the aging brain. The significance of serum antibodies reactive against a-
synuclein is not well known. We explored serum IgG levels to monomeric a-synuclein in dementia with Lewy bodies (DLB)
and Alzheimer’s disease (AD) with a novel and validated highly sensitive ELISA assay. Antibody levels revealed stark
differences in patients compared to healthy subjects and were dependent on diagnosis, disease duration and age. Anti-a-
synuclein IgG levels were increased in both patient groups, but in early DLB to a much greater extent than in AD. Increased
antibody levels were most evident in younger patients, while with advanced age relatively low levels were observed, similar
to healthy individuals, exhibiting stable antibody levels independent of age. Our data show the presence of differentially
altered IgG levels against a-synuclein in DLB and AD, which may relate to a disturbed a-synuclein homeostasis triggered by
the disease process. These observations may foster the development of novel, possibly preclinical biomarkers and
immunotherapeutic strategies that target a-synuclein in neurodegenerative disease.
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Introduction
Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB)
are the most frequent forms of dementia and belong to the
tauopathies and synucleinopathies, respectively. Clinical diagnosis
and distinction of the disorders are often difficult especially at very
early and late stages of disease, with a definite diagnosis usually
only being made upon autopsy. Despite the revised clinical
guidelines, the consensus criteria for the diagnosis of DLB [1] is
frequently lacking sensitivity, especially at disease onset [2]. In
addition, there is considerable clinical and pathological overlap
between the two disorders [3]. In AD, Lewy bodies and Lewy
neurites are frequently observed [4], and DLB often meets the
histological criteria of AD [1]. Therefore, early, preferably
preclinical diagnosis of an evolving dementia and a better
diagnostic distinction of DLB versus AD is an important goal.
To meet this challenge, the development of sensitive and specific
biomarkers is crucial.
The biochemical markers Amyloid beta (Ab) 1–42 and tau in
the cerebrospinal fluid (CSF), that are decreased and elevated in
AD, respectively, offer reasonable sensitivity and specificity for the
diagnosis of AD, especially if analyzed together, however, their
ability to differentiate AD from other forms of dementia, such as
DLB, is limited [5,6]. Increasingly, a-synuclein, a protein involved
in synaptic plasticity and neurotransmission, is being explored as
an additional CSF biomarker, and evidence may point to lower
levels in Parkinson’s disease (PD) patients compared to controls
[5,7–9]. The presence of antibodies against a-synuclein in the
peripheral blood was first published by Woulfe et al. 2002 [10]
and later by Papachroni et al. 2007 [11] but no significant
differences of antibody levels were observed in idiopathic PD
compared to controls. However, Gruden et al. detected elevated
antibody levels against a-synuclein in patients with PD [12–14].
This is in contrast to recent observations by Besong-Agbo et al.
describing decreased anti-a-synuclein antibody levels in PD but
not AD patients compared to healthy controls [15]. Very recently,
Smith et al. observed increased serum antibody concentrations
within the PD patient group only if disease duration was less than
4 years [16].
Alpha-synuclein is an abundant self-protein and is found at low
concentration extracellularly in serum and CSF and intracellularly
at relatively higher concentration in neurons and blood cells
[17,18]. Alpha-synuclein can endogenously be transferred from
neurons to astroglial cells and may promote a local inflammatory
response [19]. Moreover, it was recently recognized that prion-like
spread of a-synuclein aggregates into neurons may lead to Lewy
body pathology and neuronal loss in PD [20–23]. Importantly, in
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the mouse model Lewy body pathology could be prevented by
active immunization with a-synuclein or direct transfer of
antibodies against a-synuclein [24,25].
The natural antibody repertoire against a-synuclein is likely
being shaped by positive B cell selection and a-synuclein
presentation to lymphocytes. In neurodegenerative disease
blood-borne monocytes/macrophages or activated CNS (micro)g-
lia may act as antigen-presenting cells (APC) [26,27] and drive B
cell activation and selection, resulting in production of affinity-
matured antibodies to a-synuclein. Therefore, delineation of anti-
a-synuclein antibodies in healthy and diseased individuals could
give important insight for the discovery of novel immune
biomarkers and, in addition, for the development of a-synuclein
targeted immunotherapies. In this study, we measured IgG levels
against a-synuclein in the serum of DLB, AD and non-demented
control subjects and analyzed their relation to other demographic
factors, such as age at blood draw, gender, disease duration and
severity.
Materials and Methods
Patients and Controls
The ethics committee of the Eberhard-Karls-University Tu¨bin-
gen approved this study (ethics nr. 314/06) and written informed
consent was received by all individuals participating in the study. If
capacity to consent of participants was compromised by any
means, based on neuropsychological testing and physicians’
judgment, legal guardians consented on their behalf. All partic-
ipants who declined to participate or otherwise did not participate
in the study were not disadvantaged in any other way.
Serum samples were collected at the Department of Psychiatry
and Psychotherapy and the Department of Neurodegeneration,
Eberhard-Karls-University Tu¨bingen. A total of 19 DLB patients,
15 AD patients and 16 age-matched, non-demented controls (C)
were investigated. AD patients met the diagnostic criteria of
probable AD according to DSM-4, ICD-10 and NINCDS-
ADRDA (National Institute of Neurological and Communicative
Disorders and Stroke-Alzheimer’s Disease and Related Disorders
Association). DLB was diagnosed according to the criteria of
McKeith et al. [1] with central features, and at least one core
feature being present. Severity of dementia was assessed by mini-
mental state examination (MMSE) [28]. Patients with presence of
cerebrovascular disease on brain imaging, a physical or brain
disorder that could account for the clinical picture were excluded.
Healthy control individuals were recruited from healthy spouses or
volunteers that did not complain of any cognitive problems, and
who were unremarkable in cognition and cognitive flexibility.
Data and Statistical Analysis
Data are shown as mean 6 standard deviation (SD). Statistical
evaluation and regression analysis were carried out as indicated
using the GraphPad Prism 5 software (La Jolla, CA; USA). Groups
were compared by unpaired or paired two tailed t-test, as
indicated. Analysis of multiple diagnostic groups was performed
with one-way ANOVA followed by Tukey’s multiple comparison
test. Demographics were analyzed by unpaired two-tailed t-test,
one-way ANOVA or x2-test, as appropriate. Correlations were
assessed by Spearman correlation. Receiver operating character-
istic (ROC) curves, along with area under the curve (AUC) and p-
values were generated with GraphPad Prism. The significance
level was generally set at p,0.05 (***p,0.001, highly significant;
**p = 0.001 – 0.01, very significant; *p = 0.01 – 0.05, significant;
.0.05 not significant).
Measurement of IgG Antibodies against a-synuclein
Serum IgG levels against a-synuclein were measured by a
sandwich ELISA developed in our laboratory as described below.
Alpha-synuclein produced in E. coli was analyzed for purity by
Western immunoblot (not shown). 96 well plates (Polysorb, Nunc,
Wiesbaden, Germany) were coated with 3 mg/ml recombinant
human a-synuclein in TBS buffer and incubated overnight at 4uC.
Plates were washed in TBS/Tween (TBS, 0.1% Tween) and
blocked in TBS/Tween plus proprietary proteins. Duplicate wells
were incubated with serum diluted in TBS/Tween for 2 hours.
After washing, wells were incubated with biotinylated polyclonal
goat anti-human IgG (Sigma-Aldrich, Deisenhofen, Germany)
diluted 1:5000 in TBS/Tween. Avidin-Biotin (Roche, Mannheim,
Germany) was used as an amplification step and TMB as the
peroxidase substrate. The colour reaction was stopped after 30
minutes. Absorbance (OD, optical density) as a measure of
antibody reactivity or antibody level was measured at 450nm in an
ELISA reader (Sunrise, Tecan, Switzerland). Corrected specific
IgG reactivity against a-synuclein was calculated by subtraction of
unspecific background signal (a-synuclein coated wells, serum
omitted) from specific signal (serum incubation). A monoclonal
mouse antibody to anti-a-synuclein (clone Syn211, Sigma-Aldrich,
Deisenhofen, Germany) served as coating control. Specificity of
measured anti-a-synuclein IgG was further demonstrated in a
competition (blocking) assay by pre-incubation of serum with
recombinant a-synuclein prior to ELISA analysis. In addition, a
solid phase a-synuclein pre-adsorption assay by means of a well to
well serum transfer was performed (not shown).
Results
Patient Population and Demographics
Details of the population demographics are shown in Table 1.
Disease duration, age at disease onset and MMSE was not
significantly different between DLB and AD by unpaired two
tailed t-test with p-values of 0.86, 0.09 and 0.88, respectively. Age
did not differ significantly between the groups including the non-
demented controls (C) by one-way ANOVA (p= 0.08), while
gender was significantly different between all groups by x2-test
(p = 0.018), due to the high prevalence of female patients in the
AD group.
Measurement of Anti-a-synuclein IgG
The ELISA was extensively tested with various modifications to
achieve utmost specificity and reliability. After testing a wide range
of serum dilutions (not shown) a dilution of 1:100 was chosen,
because at this dilution measured IgG levels fell mostly within the
range of the assay and were above the detection limit (unspecific
background +3SD). The linear, dynamic range of the assay was
from approx. 0.8 to 2.5 OD. Measurements were replicated in at
least 3 independent assays using the same sera (not shown), and
interassay variation was 30% at a maximum. Yet, to reach the
highest consistency for a reliable comparison of anti-a-synuclein
IgG levels, only data are shown that were generated within the
same experimental run. The unspecific background staining (a-
synuclein coated wells, only serum omitted) was very low with an
OD of 0.06760.018 (mean 6 SD). The anti-a-synuclein coating
control antibody (clone Syn211) yielded ODs of 2.6160.13,
1.2560.12 and 0.5660.02 at dilutions of 1:509000, 100’000 and
500’000, respectively.
Blocking of Serum Anti-a-synuclein IgG Antibodies
To validate the specificity of anti-a-synuclein IgG measure-
ments, serum was pre-incubated at 20uC for 1 hour with
Natural Antibodies against a-Synuclein
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recombinant human a-synuclein at 5 mg/ml in order to bind free
serum antibodies against a-synuclein. Pre-treated sera from the 19
DLB patients and the 16 non-demented control individuals (not
performed for AD samples) were subsequently measured by
ELISA, shown in Fig. 1. The addition of a-synuclein resulted in
diminished anti-a-synuclein IgG levels in all sera. Antibodies to a-
synuclein were efficiently reduced to a mean absorbency of 0.30
OD (from 0.80) and 0.29 OD (from 0.48) in DLB and controls,
respectively. The reduction of anti-a-synuclein reactivity was
highly significant for both groups (p,0.0001) by paired two-tailed
student t-test, indicating the specificity of the ELISA.
Serum Levels of Anti-a-synuclein IgG in DLB, AD and
Controls
DLB and AD patients revealed elevated mean serum IgG levels
against a-synuclein compared to non-demented control individu-
als, shown in Fig. 2, while mean antibody levels were similar in
DLB and AD patients. The difference of IgG levels between the
three groups was significant by ANOVA (p= 0.0470) and DLB
significantly differed from controls by Tukey’s multiple compar-
ison test (p,0.05). Very high antibody levels above 1 OD were
only observed in the patient groups. An OD greater than 0.7 was
observed in 10 of 19 (52.6%) DLB patients and 7 of 15 (46.7%)
AD patients. By contrast, only 3 of 16 (18.8%) controls reached
that level. Although IgG levels considerably overlapped between
the groups, ODs greater than 1 were only observed in patients
(n = 4) and ODs below 0.43 essentially in controls (n = 8) and only
one DLB patient. It is of note that the distribution of IgG levels
against a-synuclein was spread out much more in DLB and AD
than controls, reflected by higher standard deviations/variances of
mean IgG levels in the patient groups (Tab. 1). The 95%
confidence interval (CI) of the mean was 0.354–0.615 OD, 0.568–
1.034 OD and 0.551–0.952 OD for controls, DLB and AD
patients, respectively.
Influence of Age on Serum Anti-a-synuclein Antibody
Levels
Linear regression of age with IgG levels to a-synuclein is
illustrated in Fig. 3 for the DLB, AD and the non-demented
control group (C). For DLB patients correlation of anti-a-synuclein
IgG levels with age was strongly negative and highly significant by
Spearman correlation p= 0.0074. Thus, serum IgG levels were
significantly higher in younger compared to DLB patients with
advanced age. AD patients showed a negative, but non-significant
trend of IgG levels with age and, by contrast, controls exhibited
slightly rising IgG levels with age. R square was 0.0048, 0.421,
0.063 for controls, DLB and AD, respectively. Only for DLB the
slope deviated highly significant from zero (p= 0.0027). Until the
age of about 75 years, DLB and AD patients exhibited
considerably higher anti-a-synuclein IgG levels that were all
Table 1. Demographics and anti-a-synuclein IgG levels of DLB, AD and control (C) group.
n (f/m) Age (y)
Disease
duration (y)
Age at disease
onset (y) MMSE (score) anti-a-syn IgG (OD)
C 16 (9/7) 70.964.6 – – n.d. 0.48460.245 (CI 0.354–0.615)
DLB 19 (6/13) 75.167.7 3.462.8 72.567.3 18.567.7 0.80160.484 (CI 0.568–1.034)
AD 15 (12/3) 70.367.1 3.362.2 67.968.0 18.865.5 0.75160.363 (CI 0.551–0.952)
Data are shown as mean 6 SD. AD=Alzheimer’s disease; C = non-demented controls; CI = 95% confidence interval of the mean; DLB = dementia with Lewy bodies;
f = female; m=male; MMSE =Mini-mental state examination; n = number of individuals; n.d. = not done; OD=optical density; syn = synuclein; y = years.
doi:10.1371/journal.pone.0064649.t001
Figure 1. Blocking of serum anti-a-synuclein IgG antibodies.
Pre-incubation of serum from DLB patients and non-demented controls
(C) with recombinant human a-synuclein (a-syn) efficiently bound
serum IgG against a-synuclein, indicating the specificity of the ELISA
measurements. Anti-a-synuclein IgG reactivity from DLB and controls
(C) was blocked by an average of 55.8 and 43%, respectively. The boxes
upper and lower borders represent the 25th and 75th percentile,
whiskers indicate the 10 to 90 percentile, and the solid line within the
box marks the mean, the thin line the median of the data points.
p,0.0001 by paired two-tailed student t-test.
doi:10.1371/journal.pone.0064649.g001
Figure 2. Serum levels of anti-a-synuclein IgG in DLB, AD and
controls. Comparison of serum IgG levels against a-synuclein in DLB,
AD and control group (C). By ANOVA there was a significant difference
between the groups (p = 0.0470) and anti-a-synuclein IgG was
significantly higher in DLB compared to non-demented controls
(p,0.05) by Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0064649.g002
Natural Antibodies against a-Synuclein
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above the regression line of the control group; this difference
between patients and controls diminished at a higher age.
Influence of Disease Duration on Serum Anti-a-synuclein
IgG Levels
In DLB and AD patients linear regression of disease duration
and serum anti-a-synuclein IgG levels showed associations in
opposite direction, shown in Fig. 4. There was a strong positive
relationship between disease duration and anti-a-synuclein IgG
levels in AD, reaching a p-level of 0.010 by Spearman correlation.
By contrast, in DLB longer disease span was linked to lower IgG
levels, with highest levels observed at very early stages (p = 0.056
by Spearman correlation). The slope deviated highly significant
from zero for AD (p,0.0001), but not for DLB (p= 0.090). The
difference between the slopes of both patient groups was highly
significant (p,0.0001). R square was 0.752 and 0.180 for AD and
DLB, respectively.
Influence of Gender and MMSE on Serum Anti-a-
synuclein IgG Levels
There was no evidence of higher antibody levels of females
compared to males in DLB or controls (not shown). No significant
correlation was observed between disease severity (MMSE) and
anti-a-synuclein antibody levels in the patient groups (not shown).
ROC Curve Analysis to Evaluate Anti-a-synuclein IgG
Levels as a Marker of Disease
Receiver operating characteristic (ROC) curve analysis was
utilized to evaluate the potential of anti-a-synuclein IgG levels to
indicate disease, or to differentiate between DLB (Fig. 5A) and
AD (Fig. 5B). The ROC curve plots the rate (in percent) of true
positive (sensitivity) against false positive (specificity) diagnosis (C
vs. DLB or AD) for every anti-a-synuclein IgG cut-off value.
Diagnostic usefulness of the ROC curves was confirmed by the
area under the curve (AUC), which was 0.714 (95% CI: 0.543–
0.884; p = 0.031) and 0.738 (95% CI: 0.560–0.916; p= 0.024) for
DLB and AD vs. controls, respectively. ROC analysis did not
indicate significance for the discrimination between AD and DLB
patients. The dashed line (AUC=0.5) in Figures 5 indicates the
threshold where there would be no diagnostic value to anti-a-
synuclein IgG levels. The highest predictive value would be
reached when AUC=1. The maximum Youden index which
describes the performance of a diagnostic test/biomarker was used
to determine the potentially optimal anti-a-synuclein IgG cut-off
level, marked by a star in Fig. 5A and Fig. 5B, to separate AD or
DLB patients from controls. The cut-off levels that may represent
the best balance between sensitivity and specificity were at 0.52
OD for DLB, resulting in 74% sensitivity and 63% specificity, and
0.42 OD for AD, resulting in 100% sensitivity, 50% specificity.
Discussion
To correctly diagnose an evolving, potentially dementing
neurodegenerative disorder poses a great challenge even to the
specialized physician. This difficulty is particularly apparent at the
very early and late stages of disease, when neuropsychiatric
symptoms are subtle or intertwine. The great majority of these
disorders are characterized by tissue deposition of the aggregation
prone and ubiquitously expressed proteins Ab, tau and a-synuclein
[29–31]. In view of the immensely growing economic burden that
these disorders pose onto the ageing society and with regard to the
right use of existing and emerging drug therapies, an earlier and a
more precise diagnosis is urgently needed.
Alpha-synuclein plays a key role in the pathogenesis of
synucleinopathies, which comprise PD, PD dementia (PDD),
DLB and multiple system atrophy (MSA), in addition to AD
subtypes, such as the Lewy body variant of AD. In these disorders
pathological conformations of a-synuclein aggregate, accumulate
and deposit in the nervous system in the form of oligomers or
insoluble amyloid [32–34]. Because of the relative abundance of
activated cytokine producing APCs such as microglia and
macrophages in afflicted nervous system tissue [26,27], it is
reasonable to assume that an adaptive immune response would
result in the production of antibodies against a-synuclein, which
may ideally be characteristic for a particular synucleinopathy.
We developed and validated a highly sensitive and specific
ELISA to measure antibody reactivities against monomeric a-
synuclein in human serum. Intriguingly, antibody levels were
Figure 3. Influence of age on serum anti-a-synuclein antibody
levels. Linear regression of serum anti-a-synuclein IgG levels with age
for the DLB, AD and control group. The difference between the slopes
was significant (p = 0.0385). DLB and to a lesser extent AD showed
noticeably higher antibody levels at younger age compared to patients
with advanced age. The negative correlation of anti-a-synuclein IgG
levels with age in DLB patients was highly significant (p = 0.0074 by
Spearman correlation). By contrast, the control group showed a trend of
rising IgG levels with age.
doi:10.1371/journal.pone.0064649.g003
Figure 4. Influence of disease duration on serum anti-a-
synuclein IgG levels. Linear regression of serum anti-a-synuclein
IgG levels with duration of disease for DLB and AD patients. In AD
longer disease was strongly correlated with higher antibody levels
(p = 0.010 by Spearman correlation). In contrast, in DLB patients, disease
duration and anti-a-synuclein IgG levels showed a tendency of negative
correlation (p = 0.056).
doi:10.1371/journal.pone.0064649.g004
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differentially altered in DLB and AD compared to healthy control
subjects. In young patients serum IgG levels were strikingly
elevated in DLB and to a lesser extent also in AD and markedly
decreased with advancing age. By contrast, anti-a-synuclein
antibodies from controls remained stable at lower levels through-
out the aging process. Notably, antibody production was also
dependent on disease duration; DLB patients exhibited very high
IgG levels at early stages, whereas AD patients showed the reverse,
with higher levels after a prolonged disease course. Anti-a-
synuclein antibodies may be triggered by an inflammatory CNS
microenvironment, frequently present in AD and PD
[26,27,35,36] and related to the amount of a-synuclein aggrega-
tion and tissue deposition, which is likely extensive in early DLB,
in contrast to AD where a-synuclein burden may slowly rise. The
steep drop of the elevated a-synuclein-reactive antibody levels with
age in DLB and AD may be due to absorption of antibodies by
tissue-deposited a-synuclein and, in addition, pathophysiologically
related to an accelerated immunosenescence with a disturbed T
helper (Th) lymphocyte adaptive immunity [36–40]. Based on
these observations anti-a-synuclein antibodies may represent a
powerful immune biomarker for the detection of an ongoing, yet
preclinical a-synuclein associated neurodegeneration, and be of
significant help for the diagnosis of (pre)symptomatic disease,
potentially indicating the load of Lewy-body pathology. It seems
reasonable to hypothesize that an emerging a-synucleinopathy
could be revealed by increasing anti-a-synuclein IgG titers.
In this context it should be noted that according to our analysis
intergroup differences of anti-a-synuclein IgG levels between DLB
and AD seem modest and specificity and sensitivity are at this
stage not sufficient for a clinical discriminator. Also, a confirma-
tion dataset is needed to substantiate our findings. Similar changes
may occur in subjects with other prototypic synucleinopathies such
as PD and MSA which was not part of this study.
So far, only a few studies analyzed antibody reactivities against
a-synuclein in PD. Their presence was first identified in serum by
ELISA, however, there was no difference of antibody levels in PD
compared to control individuals [10]. In a Western blot analysis
serum antibodies against a-synuclein were detected in the majority
of patients with inherited PD, but the difference between
idiopathic PD and control subjects was not statistically significant
[11]. It was only recently, that higher IgG levels against a-
synuclein were described in PD especially early in the disease [12–
14,16] which was not confirmed in another study, showing lower
antibody levels [15]. In comparison, Ab the major amyloid that
accumulates in AD plaques has been studied more extensively.
Altered autoantibody reactivities against Ab have been detected in
AD, showing increased, decreased or similar antibody levels in
patients compared to controls in CSF [41] and plasma or serum
[41–48]. This conflicting data may be not only explained by
methodological differences of the employed immunoassays but
also by other influencing variables, such as age and disease
duration as observed in our study populations.
The pathophysiological relevance of autoantibodies that bind to
a-synuclein is unknown. Elevated antibody levels could play a role
for both, a beneficial immune response as part of a protective
mechanism against the accumulation of pathogenic a-synuclein or,
but probably less likely, a harmful inflammatory process that
mediates CNS damage. Analogous to the proposed homeostasis of
Ab concentrations between CNS and peripheral circulation by
anti-Ab antibodies (peripheral sink hypothesis) [33,49–51], anti-
bodies to a-synuclein may draw a-synuclein into the peripheral
circulation [52], and thereby clear the protein or its toxic
intermediates from the CNS in order to maintain a physiological
equilibrium. Antibodies could lead to immune-complex formation,
mediate phagocytosis by macrophages/microglia [53], or have a
direct proteolytic activity [54] and control potentially toxic protein
levels. Monoclonal antibodies against a-synuclein have been
shown to reduce oligomerization and increase turnover of a-
synuclein [55]. Thus, antibodies to a-synuclein may critically
influence concentration and half-life of a-synuclein in body fluids
and CNS tissue and act as chaperones to prevent a-synuclein from
forming toxic or aggregation prone conformations.
There is strong evidence of a transneuronal prion-like spread of
misfolded amyloidogenic proteins such as a-synuclein through the
extracellular compartment in neurodegenerative disease [20–23].
Therefore, therapeutic targeting of extracellular a-synuclein by
passive antibody administration, an approach currently extensively
pursued for Ab in AD clinical trials, appears feasible. In
synucleinopathies and in particular DLB this could be most
promising also later in the disease course when anti-a-synuclein
IgG levels are diminished.
Figure 5. ROC curve analysis to evaluate anti-a-synuclein IgG
levels as a marker of disease. Receiver-operator characteristic (ROC)
curves to evaluate antibody levels against a-synuclein as a diagnostic
biomarker for DLB or AD. Anti-a-synuclein IgG levels were used to
create ROC curves to differentiate DLB from controls (AUC=0.714;
p = 0.031) (Fig. 5A) and differentiate AD from controls (AUC=0.738,
p = 0.024) (Fig. 5B). No diagnostic value was reached for the
differentiation of AD from DLB (not shown). The dashed line indicates
the threshold of no diagnostic value (AUC= 0.5). Youden index was
calculated to identify cut-off levels, denoted by the star.
doi:10.1371/journal.pone.0064649.g005
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Antibodies to self-proteins such as a-synuclein or Ab can be
readily detected in the peripheral blood of healthy individuals and
are a normal part of the antibody repertoire. In contrast to the
former theory of deletion of autoreactive clones, ‘‘horror
autotoxicus’’ as coined by Paul Ehrlich, it is now anticipated that
self-reactive antibodies are playing an important role for the
biochemical and immunological homeostasis [56,57]. These
natural autoantibodies in healthy individuals may serve a
protective function by binding endogenous, perhaps toxic proteins
or by neutralizing microbes as part of a first defence barrier
throughout life [58,59].
Taken together, the presence of a-synuclein-specific antibodies
in the peripheral blood points to their potential relevance for
maintaining equilibrium of a-synuclein or its degradation products
within the CNS and the peripheral circulation. Based on our
results, the analysis of antibody reactivities against a-synuclein
may provide a means to diagnose and assess neurodegenerative
diseases where a-synuclein plays a pathophysiological role.
Moreover, the detection of elevated antibody levels against a-
synuclein could be a valuable predictor for early stage Lewy body
disease, especially in younger individuals. Thus, further explora-
tion of anti-a-synuclein antibodies as a potential diagnostic
biomarker for a-synuclein related neurodegenerative disease is
warranted.
Acknowledgments
We are grateful to the individuals who donated their blood for this study.
This work is dedicated to Prof. Dr. med. Klaus Schott, a dedicated
physician scientist and inspiring mentor, who left us suddenly and far too
early.
Author Contributions
Conceived and designed the experiments: NKK ERS SG MM BS TL ES
KS TJ MSC PK. Performed the experiments: ES NKK. Analyzed the
data: NKK ES. Contributed reagents/materials/analysis tools: PK TMJ
MSC NKK ES AJF AB GB WM TL CL MM SG. Wrote the paper: NKK
MS ERS SG MM. Clinical investigators: NKK SG MM BS TL CL WM.
References
1. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, et al. (2005) Diagnosis
and management of dementia with Lewy bodies: third report of the DLB
Consortium. Neurology 65: 1863–1872.
2. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, et al. (2006)
What best differentiates Lewy body from Alzheimer’s disease in early-stage
dementia? Brain 129: 729–735.
3. Kotzbauer PT, Trojanowsk JQ, Lee VM (2001) Lewy body pathology in
Alzheimer’s disease. J Mol Neurosci 17: 225–232.
4. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J (1989) Clinical and
pathological aspects of parkinsonism in Alzheimer’s disease. A role for
extranigral factors? Arch Neurol 46: 651–657.
5. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, et al. (2008) Direct
quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in
patients with neurodegeneration. Exp Neurol 213: 315–325.
6. Stefani A, Brusa L, Olivola E, Pierantozzi M, Martorana A (2012) CSF and
clinical hallmarks of subcortical dementias: focus on DLB and PDD. J Neural
Transm 119: 861–875.
7. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, et al. (2006)
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects
with Parkinson’s disease. Biochem Biophys Res Commun 349: 162–166.
8. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, et al. (2010) DJ-1 and
alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s
disease. Brain 133: 713–726.
9. Spies PE, Melis RJ, Sjogren MJ, Rikkert MG, Verbeek MM (2009)
Cerebrospinal fluid alpha-synuclein does not discriminate between dementia
disorders. J Alzheimers Dis 16: 363–369.
10. Woulfe JM, Duke R, Middeldorp JM, Stevens S, Vervoort M, et al. (2002)
Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane
protein antibodies in PD. Neurology 58: 1435–1436.
11. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromer-
isiou G, et al. (2007) Autoantibodies to alpha-synuclein in inherited Parkinson’s
disease. J Neurochem 101: 749–756.
12. Gruden MA, Sewell RD, Yanamandra K, Davidova TV, Kucheryanu VG, et al.
(2011) Immunoprotection against toxic biomarkers is retained during Parkin-
son’s disease progression. J Neuroimmunol 233: 221–227.
13. Gruden MA, Yanamandra K, Kucheryanu VG, Bocharova OR, Sherstnev VV,
et al. (2012) Correlation between Protective Immunity to alpha-Synuclein
Aggregates, Oxidative Stress and Inflammation. Neuroimmunomodulation 19:
334–342.
14. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, et al. (2011)
alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of
Parkinson’s disease patients. PLoS One 6: e18513.
15. Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, et al. (2013)
Naturally occurring alpha-synuclein autoantibody levels are lower in patients
with Parkinson disease. Neurology 80: 169–175.
16. Smith LM, Schiess MC, Coffey MP, Klaver AC, Loeffler DA (2012) alpha-
Synuclein and Anti-alpha-Synuclein Antibodies in Parkinson’s Disease, Atypical
Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls.
PLoS One 7: e52285.
17. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, et al. (2008) Red blood
cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5: 55–
59.
18. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K (2002)
Demonstration of alpha-synuclein immunoreactivity in neuronal and glial
cytoplasm in normal human brain tissue using proteinase K and formic acid
pretreatment. Exp Neurol 176: 98–104.
19. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, et al. (2010) Direct transfer of alpha-
synuclein from neuron to astroglia causes inflammatory responses in synuclei-
nopathies. J Biol Chem 285: 9262–9272.
20. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (2008) Lewy
body-like pathology in long-term embryonic nigral transplants in Parkinson’s
disease. Nat Med 14: 504–506.
21. Li JY, Englund E, Holton JL, Soulet D, Hagell P, et al. (2008) Lewy bodies in
grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease
propagation. Nat Med 14: 501–503.
22. Jucker M, Walker LC (2011) Pathogenic protein seeding in Alzheimer disease
and other neurodegenerative disorders. Ann Neurol 70: 532–540.
23. Miller G (2008) Parkinson’s disease. Signs of disease in fetal transplants. Science
320: 167.
24. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, et al. (2012) Antibody-Aided
Clearance of Extracellular alpha-Synuclein Prevents Cell-to-Cell Aggregate
Transmission. J Neurosci 32: 13454–13469.
25. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, et al. (2005) Effects of
alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron
46: 857–868.
26. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson’s disease. Mov
Disord 23: 474–483.
27. Roodveldt C, Christodoulou J, Dobson CM (2008) Immunological features of
alpha-synuclein in Parkinson’s disease. J Cell Mol Med 12: 1820–1829.
28. Folstein MF, Folstein SE, McHugh PR (1975) ‘‘Mini-mental state’’. A practical
method for grading the cognitive state of patients for the clinician. J Psychiatr
Res 12: 189–198.
29. Galpern WR, Lang AE (2006) Interface between tauopathies and synucleino-
pathies: a tale of two proteins. Ann Neurol 59: 449–458.
30. Jellinger KA (2008) Neuropathological aspects of Alzheimer disease, Parkinson
disease and frontotemporal dementia. Neurodegener Dis 5: 118–121.
31. Wakabayashi K, Mori F, Tanji K, Orimo S, Takahashi H (2010) Involvement of
the peripheral nervous system in synucleinopathies, tauopathies and other
neurodegenerative proteinopathies of the brain. Acta Neuropathol 120: 1–12.
32. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, et al. (2009)
Neuropathological assessment of Parkinson’s disease: refining the diagnostic
criteria. Lancet Neurol 8: 1150–1157.
33. Morgan D (2005) Mechanisms of A beta plaque clearance following passive A
beta immunization. Neurodegener Dis 2: 261–266.
34. Schulz-Schaeffer WJ (2010) The synaptic pathology of alpha-synuclein
aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s
disease dementia. Acta Neuropathol 120: 131–143.
35. Fiala M, Cribbs DH, Rosenthal M, Bernard G (2007) Phagocytosis of amyloid-
beta and inflammation: two faces of innate immunity in Alzheimer’s disease.
J Alzheimers Dis 11: 457–463.
36. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation
in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in
either disorder? Int Rev Neurobiol 82: 235–246.
37. Antonaci S, Garofalo AR, Chicco C, Polignano AV, Pugliese P, et al. (1990)
Senile dementia, Alzheimer type: a distinct entity in the immunosenescence?
J Clin Lab Anal 4: 16–21.
38. Richartz E, Batra A, Simon P, Wormstall H, Bartels M, et al. (2005) Diminished
production of proinflammatory cytokines in patients with Alzheimer’s disease.
Dement Geriatr Cogn Disord 19: 184–188.
39. Richartz E, Stransky E, Batra A, Simon P, Lewczuk P, et al. (2005) Decline of
immune responsiveness: a pathogenetic factor in Alzheimer’s disease? J Psychiatr
Res 39: 535–543.
Natural Antibodies against a-Synuclein
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e64649
40. Richartz-Salzburger E, Batra A, Stransky E, Laske C, Kohler N, et al. (2007)
Altered lymphocyte distribution in Alzheimer’s disease. J Psychiatr Res 41: 174–
178.
41. Du Y, Dodel R, Hampel H, Buerger K, Lin S, et al. (2001) Reduced levels of
amyloid beta-peptide antibody in Alzheimer disease. Neurology 57: 801–805.
42. Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Burger K, et
al. (2005) Decreased serum amyloid beta(1–42) autoantibody levels in
Alzheimer’s disease, determined by a newly developed immuno-precipitation
assay with radiolabeled amyloid beta(1–42) peptide. Biol Psychiatry 57: 813–
816.
43. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, et al. (2001)
Autoantibodies to amyloid-beta and Alzheimer’s disease. Ann Neurol 49: 808–
810.
44. Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, et al. (2005)
Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma
of Alzheimer’s disease patients. J Biol Chem 280: 17458–17463.
45. Nath A, Hall E, Tuzova M, Dobbs M, Jons M, et al. (2003) Autoantibodies to
amyloid beta-peptide (Abeta) are increased in Alzheimer’s disease patients and
Abeta antibodies can enhance Abeta neurotoxicity: implications for disease
pathogenesis and vaccine development. Neuromolecular Med 3: 29–39.
46. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, et al. (2002) Patients
with Alzheimer disease have lower levels of serum anti-amyloid peptide
antibodies than healthy elderly individuals. Exp Gerontol 37: 943–948.
47. Xu S, Gaskin F (1997) Increased incidence of anti-beta-amyloid autoantibodies
secreted by Epstein-Barr virus transformed B cell lines from patients with
Alzheimer’s disease. Mech Ageing Dev 94: 213–222.
48. Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, et al. (2008)
Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer’s disease
and normal controls. Brain Res 1219: 169–179.
49. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al. (2001)
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and
decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc
Natl Acad Sci U S A 98: 8850–8855.
50. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T (2001)
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide
reduces Alzheimer’s disease-associated pathology in transgenic mice. Am J Pathol
159: 439–447.
51. Szabo P, Relkin N, Weksler ME (2008) Natural human antibodies to amyloid
beta peptide. Autoimmun Rev 7: 415–420.
52. Brendza RP, Holtzman DM (2006) Amyloid-beta immunotherapies in mice and
men. Alzheimer Dis Assoc Disord 20: 118–123.
53. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. (2000) Peripherally
administered antibodies against amyloid beta-peptide enter the central nervous
system and reduce pathology in a mouse model of Alzheimer disease. Nat Med
6: 916–919.
54. Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, et al. (2008)
Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 283:
4714–4722.
55. Nasstrom T, Goncalves S, Sahlin C, Nordstrom E, Screpanti Sundquist V, et al.
(2011) Antibodies against alpha-synuclein reduce oligomerization in living cells.
PLoS One 6: e27230.
56. Dighiero G, Rose NR (1999) Critical self-epitopes are key to the understanding
of self-tolerance and autoimmunity. Immunol Today 20: 423–428.
57. Silverstein AM (2001) Autoimmunity versus horror autotoxicus: the struggle for
recognition. Nat Immunol 2: 279–281.
58. Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayouba A, Malanchere E, et al.
(1998) Self-reactive antibodies (natural autoantibodies) in healthy individuals.
J Immunol Methods 216: 117–137.
59. Lacroix-Desmazes S, Mouthon L, Kaveri SV, Kazatchkine MD, Weksler ME
(1999) Stability of natural self-reactive antibody repertoires during aging. J Clin
Immunol 19: 26–34.
Natural Antibodies against a-Synuclein
PLOS ONE | www.plosone.org 7 May 2013 | Volume 8 | Issue 5 | e64649
